Lyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Lyell Immunopharma (NASDAQ:LYEL) in a report released on Thursday, Marketbeat reports. The brokerage currently has a $1.00 target price on the stock, down from their prior target price of $6.00.

Lyell Immunopharma Stock Up 5.1 %

Shares of NASDAQ LYEL opened at $1.45 on Thursday. The firm has a 50-day simple moving average of $2.39 and a 200-day simple moving average of $2.24. The stock has a market capitalization of $369.66 million, a price-to-earnings ratio of -1.61 and a beta of -0.40. Lyell Immunopharma has a 52 week low of $1.18 and a 52 week high of $3.41.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Monday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. As a group, equities research analysts expect that Lyell Immunopharma will post -0.85 EPS for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC raised its holdings in Lyell Immunopharma by 9.3% in the 1st quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock valued at $109,000 after buying an additional 4,170 shares during the period. Profund Advisors LLC increased its holdings in Lyell Immunopharma by 20.0% in the 3rd quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock valued at $108,000 after purchasing an additional 12,225 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in Lyell Immunopharma by 109.7% in the third quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after purchasing an additional 14,229 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth $31,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Lyell Immunopharma by 67.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 48,855 shares of the company’s stock worth $109,000 after buying an additional 19,718 shares during the period. 66.05% of the stock is owned by hedge funds and other institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.